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Abstract
Background: Mesenchymal stem cells (MSCs) have been considered to be the attractive vehicles for delivering
therapeutic agents toward various tumor diseases. This study was to explore the distribution pattern, kinetic
delivery of adenovirus, and therapeutic efficacy of the MSC loading of E1A mutant conditionally replicative
adenovirus Adv-Stat3(-) which selectively replicated and expressed high levels of anti-sense Stat3 complementary
DNA in breast cancer and melanoma cells.
Methods: We assessed the release ability of conditionally replicative adenovirus (CRAd) from MSC using crystal
violet staining, TCID50 assay, and quantitative PCR. In vitro killing competence of MSCs carrying Adv-Stat3(-) toward
breast cancer and melanoma was performed using co-culture system of transwell plates. We examined tumor
tropism of MSC by Prussian blue staining and immunofluorescence. In vivo killing competence of MSCs carrying
Adv-Stat3(-) toward breast tumor was analyzed by comparison of tumor volumes and survival periods.
Results: Adv-Stat3(-) amplified in MSCs and were released 4 days after infection. MSCs carrying Adv-Stat3(-) caused
viral amplification, depletion of Stat3 and its downstream proteins, and led to significant apoptosis in breast cancer
and melanoma cell lines. In vivo experiments confirmed the preferential localization of MSCs in the tumor
periphery 24 hours after tail vein injection, and this localization was mainly detected in the tumor parenchyma
after 72 hours. Intravenous injection of MSCs carrying Adv-Stat3(-) suppressed the Stat3 pathway, down-regulated
Ki67 expression, and recruited CD11b-positive cells in the local tumor, inhibiting tumor growth and increasing the
survival of tumor-bearing mice.
Conclusions: These results indicate that MSCs migrate to the tumor site in a time-dependent manner and could
be an effective platform for the targeted delivery of CRAd and the amplification of tumor killing effects.
Keywords: Mesenchymal Stem Cell, Conditionally Replicative Adenovirus, Cell Carrier, Signal Transducer and Activa-
tor of Transcription 3 (Stat3), Breast cancer
Background
Malignant tumor remains one of the leading causes of
mortality throughout the world, and new treatments are
urgently needed [1-3]. In addition to surgery, radiotherapy,
and chemotherapy, oncolytic viruses have emerged in
recent years as a promising novel class of therapeutics for
the treatment of human cancers [4-6]. Among these
viruses, conditionally replicative adenoviral agents (CRAd)
have been designed to replicate in tumor cells, whereby
the virus can self-amplify and spread in the tumor from an
initial infection of only a few cells [7-9]. In our previous
studies, we constructed many mutants of CRAd and vali-
dated their selective antitumor activities [10-12]. However,
the effective use of CRAd in clinical applications has been
limited by sequestration in the liver and reticuloendothe-
lial system [13-15], inefficient virus delivery to the tumor
site [6,16,17], and rapid elimination as a result of immune
clearance [18-20]. Thus, several approaches have been
exploited to overcome the limitations, including genetic
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any medium, provided the original work is properly cited.alteration of the virus [21,22], nanotechnology modifica-
tions [23], and the application of cell carriers, such as cyto-
toxic T-lymphocytes [20], neural stem cells [24,25], and
mesenchymal stem cells (MSCs) [26-28]. Among these
cell carrier systems, MSCs are considered to be the most
attractive candidate for viral delivery to the tumor site due
to ethical and technical convenience, poor immunogeni-
city, and genetic stabilization [29]. MSCs have been shown
to migrate toward malignant tumors [26,28-30] and track
microscopic metastasis [27], while the molecular mechan-
ism underlying the tumor-directed migration of MSCs has
not been completely elucidated [31]. MSCs engineered
with CRAd have been indicated to deliver viruses into
lung metastases of breast carcinoma [28], ovarian cancer
[4], and intracranial glioma [26,32]. However, information
regarding the kinetic process underlying MSC trafficking
to tumors, its in vivo distribution pattern, and the release
of adenovirus carrying anti-sense complementary DNA
from MSCs is still lacking.
In the present study, we investigated the ability of MSCs
to deliver an E1A mutant CRAd targeting Stat3 to ortho-
topic breast cancer. The E1A mutant was engineered with
a 27-bp deletion in the E1A CR2 region necessary for reti-
noblastoma (Rb) protein binding to attenuate viral replica-
tion and cytolysis in normal quiescent tissues but not in
tumor cells [11,12]. We demonstrate that Adv-Stat3(-) can
be loaded by MSCs, exponentially amplified up to a cer-
tain limitation, and eventually released. In vivo experi-
ments show that intravenous injections of MSCs loaded
with Adv-Stat3(-) can preferentially home to the tumor
site, and the number of homing cells increases gradually
with time. Moreover the Adv-Stat3(-) engineered MSCs
carries anti-sense target complementary DNA to the
tumor site and suppresses Stat3 expression and its down-
stream molecules, thus inhibiting tumor growth and
increasing the survival of tumor-bearing mice. Taken
together, we show that MSCs represent an amplification
site for E1A mutant CRAd, allowing previous viral stocks
to be protected until it can be delivered and released into
the tumor in a time-dependent manner.
Methods
Cells Isolation and Culture
Human MSCs were isolated from the bone marrow of nor-
mal individuals undergoing bone marrow harvest for allo-
geneic bone marrow transplantation in our department
(Hematological Center, Tongji Hospital, Huazhong Univer-
sity of Science and Technology) after obtaining informed
consent according to institutional guidelines under the
approved protocol. Briefly, mononuclear cells were sepa-
rated by centrifugation over a Ficoll-Hypaque gradient
(Sigma Chemical Co., St. Louis, MO) and suspended in a-
MEM medium containing 20% fetal bovine serum (Life
Technologies, Inc., Rockville, MD), L-glutamine, and
penicillin-streptomycin. After 3 days, the non-adherent
cells were removed by washing with PBS, and the mono-
layer of adherent cells were cultured until they reached
confluence. Cells were trypsinized using tryple™ express
(Invitrogen Co., Carlsbad, CA) and used for experiments at
passages three to eight. For identification, the cells were
trypsinized, washed with PBS, and then reacted with FITC-
labeled anti-CD34, PE-labeled anti-CD44, FITC-labeled
anti-CD45, FITC-labeled anti-CD19, PE-labeled anti-
CD90, and PE-labeled anti-CD105 antibodies (Biolegend,
San Diego, CA, USA). After washing with PBS, the expres-
sion level of these molecules was determined by flow cyto-
metry. The isotope antibodies were used as negative
controls.
Human umbilical vein endothelial cells (HUVEC) were
isolated and cultured as described previously [33]. The
human embryonic kidney 293, MDA-MB-231 breast can-
cer cell line, and MDA-MB-435 melanoma cell line [34]
were obtained from the American Type Culture Collection
(ATCC) in 2008 and maintained in DMEM and RPMI-
1640 medium containing 10% FBS, L-glutamine, and peni-
cillin-streptomycin at 37°C in a humidified 5% CO2
atmosphere.
In Vitro Differentiation of MSCs
For adipogenic differentiation, the MSCs were maintained
in medium containing 1 μM dexamethasone, 0.35 mM
hydrocortisone, 100 μg/mL 3-isobutyl-1-methylxanthine,
0.1 μg/mL insulin, and 60 μM indomethacin. Two weeks
later, the cells were fixed and stained with Oil-red O
(Sigma). Osteoblast differentiation was performed by cul-
turing MSCs in medium plus 10 μM dexamethasone, 0.1
mM ascorbic acid, and 10 mM b-glycerophosphate. Three
weeks later, the cells were washed, fixed, and stained with
Alizarin red. To induce chondrogenic differentiation,
MSCs were pelleted and maintained in medium with 2%
FBS and 10 ng/mL TGF-b3. After 14 days, the pellets were
formalin-fixed, frozen, and cryostat sections were stained
with Alcian blue (Sigma).
Recombinant Adenoviruses
The conditionally replicative adenovirus Adv-anti-sense
Stat3 (Adv-Stat3(-)) was driven from Adenovirus 5
through the deletion of amino acids 121-129 in E1A CR2
and the replacement of ADP open reading frame in the E3
region by a fragment of reverse Stat3 cDNA (bases 960-
190) (12). Replication-defective adenovirus Adv-GFP was
described previously [35]. The wild-type adenovirus Adv-
wt was obtained from ATCC.
Recombinant Adenovirus Release from MSCs In Vitro
MSCs plated in 24-well plates were infected with adeno-
virus. At indicated time points, the cells were fixed and
stained with 1% crystal violet in 4% formaldehyde for
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remove excess dye. Plate images were captured with a
Kodak DC260 digital camera (Kodak, Rochester, NY).
For the viral replication assay, the infected MSCs were
harvested at indicated time points and cell lysates were
prepared to isolate the viral DNA and total cell DNA
using the QIAamp DNA Blood kit (Qiagen, Valencia, CA).
Real-time PCR targeting the viral fiber region was per-
formed to quantitatively evaluate the adenoviral DNA
copy number. An internal GAPDH control was used to
normalize the results. The primer sequences targeting
fiber and GAPDH were as follows: fiber sense, 5’ -AAA
TGT GGC AGT CAA ATA C-3’; fiber anti-sense, 5’-ATA
GGT TAG GCA TAA ATC C-3’; GAPDH sense, 5’-ACG
GAT TTG GTC GTA TTG GG -3’; GAPDH anti-sense,
5’-TGA TTT TGG AGG GAT GTC GC -3’.
TCID50
Viral yield was determined by the limiting dilution
method, known as the determination of 50% tissue culture
infective dose, described previously [12]. The data from
three separate infection studies were expressed as plaque-
forming units per milliliter.
In Vitro Cancer Cell Cytotoxicity of Adenovirus Loaded
MSCs
MDA-MB-231, MDA-MB-435, and HUVEC cells were
trypsinized and plated in the lower chambers of transwell
plates; PBS, MSC, Adv-Stat3(-), and MSC/Adv-Stat3(-)
were added to the upper chambers of the transwell plates.
After 3 days, the cells in the lower chamber were har-
vested and stained using the annexin-V/PI apoptosis kit
(Bender MedSystems, Vienna, Austria) according to the
manufacturer’s instructions. Apoptotic cells were counted
using a FACScan flow cytometer. The data were analyzed
using cell fit software.
In Situ Hybridization
Slides were pre-hybridized for 30 min at 37°C. Hybridiza-
tion was carried out overnight at 42°C with 1 μg/mL rho-
damine-conjugated viral fiber oligonucleotide probe
complementary to the fiber coding region (5-GGA ACT
GGC CTT AGT TTT GAC AGC ACA GGT GCC ATT
ACA G-3) [35]. Negative controls were similarly processed
by omitting the probe. The results were observed under a
fluorescent microscope.
Western Blot Analysis
Total proteins were extracted by lysing the cells in buffer
containing 50 mM Tris (pH 7.4), 150 mM NaCl, 0.5% NP-
40, 50 mM NaF, 1 mM Na3VO4, 1 mM phenylmethylsul-
fonyl fluoride, 25 mg/mL leupeptin, and 25 mg/mL aproti-
nin. The lysates were cleared by centrifugation and the
supernatants collected. Equal amounts of protein lysate
were used for Western blot analyses using the indicated
antibodies. Specific signals were visualized with NBT/
BCIP.
Mouse Tumor Model
F e m a l ea t h y m i cB A L B / cm i c e( 3t o4w e e k so l d )w e r e
obtained from the Animal Experimental Center (Shanghai,
China). The mice were used in accordance with institu-
tional guidelines under the approved protocols. MDA-
MB-231 cells (2 × 10
6) were suspended in 100 μL PBS and
injected into the mammary fat pad of nude mice. After
20 days, most mice grew an orthotopic tumor approxi-
mately 4 mm in diameter. After the indicated treatments,
tumors were measured with calipers in two dimensions
every 4 days, and the volume was calculated as length ×
width
2 ×0 . 5 2 .
Survival Analysis
Twenty days after MB-MDA-231 tumor cell implantation,
the mice were injected with 1 × 10
6 MSC/Adv-Stat3(-)
(n = 8), an equivalent dose of Adv-Stat3(-) (n = 8) and
MSCs (n = 8). Negative control mice (n = 8) received PBS.
All mice were followed daily until death. None of the mice
had to be sacrificed because of excessive bleeding, open
wound infection, moribund status, or cachexia. Survival
data were plotted on a Kaplan-Meier curve. The difference
in survival was determined by the log rank test.
Immunohistochemistry
Immunohistochemical analyses of frozen sections were
performed as described previously [36].
Statistics Analyses
All experiments were repeated three times unless other-
wise specified. Data were analyzed using independent sam-
ple t tests and are expressed as mean ± SD. A p-value <
.05 was considered significant. Statistical analyses were
performed using SPSS software version 13.0 (SPSS Inc.,
Chicago, IL).
Results
Characterization of MSCs and the Transfection Efficiency
of Adenovirus
Given the lack of a specific marker in MSCs [31,37], flow
cytometry and immunofluorescence were used to validate
that the isolated cells were negative for typical hemato-
poietic antigens CD34, CD45, and CD19 and positive for
CD44, CD90, and CD105 (Figure 1A and 1C). The pro-
portion of cells expressing CD34, CD45, CD19, CD44,
CD90, and CD105, which were analyzed from 5 indepen-
dent samples, were 3.8% ± 2.3%, 2.2% ± 1.5%, 4.0% ± 1.3%,
96.6% ± 3.2%, 97.5% ± 2.1%, and 94.1% ± 4.1% (Figure 1B).
The MSCs had a differentiation capability for osteogenesis,
chondrogenesis, and adipogenesis (Figure 1D).
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the replication-defective vector Adv-GFP. The represen-
tative transfection image of 500 multiplicity of infection
(MOI) is shown in Figure 1E. Flow cytometry revealed
t h ee f f i c i e n c ya t4 8h o u r sa f t e rt r a n s f e c t i o nw a sd o s e -
dependent and reached 96.4% ± 1.2% at 500 MOI (Figure
1F). To directly verify the E1A-mutant CRAd loading
capability, the MSCs were infected with 500 MOI Adv-
Stat3(-). Seventy-two hours after infection, electron
microscopy verified the presence of intracellular viral
particles in the MSCs (Figure 1G).
Adv- Stat3(-) Exponentially Amplified in MSCs and Were
Eventually Released
After confirming MSCs could efficiently load Adv-Stat3
(-), we aimed to assess whether and when the adenovirus
is released from the cell using Adv-GFP, Adv-wt, and
Adv-Stat3(-). We hypothesized the release of adenovirus
was a result of MSC lysis. Crystal violet staining showed
Adv-Stat3(-) up to 500 MOI was released from MSCs
after 4 days, and this capability was stronger on day 5
(Figure 2A). The negative control for Adv-GFP did not
display any competence for release, whereas Adv-wt had
Figure 1 Identification of expanded human MSCs and adenovirus transfection efficiency. (A) Representative histogram overlays of FACS
analysis showing the MSC antigen profile. The blue peak represents the specific PE-labeled antibodies: CD34, CD45, CD19, CD44, CD90, and
CD105. The red peak represents the corresponding isotope antibodies. (B) Positive expression of CD34, CD45, CD19, CD44, CD90, and CD105 in
five independent samples was expressed as mean ± SD as evaluated by FACS. (C) Immunostaining of CD34, CD45, CD19, CD44, CD90, and
CD105 in one representative sample as observed under a confocal microscope. Negative controls were performed by using the corresponding
isotope antibodies. Red, PE-labeled antibodies; blue, DAPI. (D) Representative photographs showing the in vitro differentiation of MSCs into the
osteogenic, adipogenic, and chondrogenic lineages. Undifferentiated MSCs were dyed with hematoxylin and eosin. (E) Representative images
depicting the transfection of MSCs with 500 MOI Adv-GFP. Forty-eight hours after transfection, MSCs carrying GFP were observed under bright
field (upper panel) and fluorescent field (lower panel). (F) Transfection efficiencies at different Adv-GFP titers after 48 hours in three independent
MSC samples were expressed as mean ± SD as evaluated by FACS. (G) Electron micrographs showing viral particles in MSCs. MSCs were infected
with 500 MOI Adv-Stat3(-). Seventy-two hours later, MSCs were collected and prepared to be observed under an electron microscope.
Adenovirus particles in the MSCs were shown using the black arrow. C, scale bar = 5 μm; D, scale bar = 10 μm; E, scale bar = 10 μm; G, left
scale bar = 2 μm, right scale bar = 200 nm).
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Further analysis using the TCID50 method to examine
the amount of virus released from MSCs found the
amount of virus released into the culture medium mark-
edly increased from day 3 (10
3.7pfu/mL) to a high level of
10
5.9pfu/mL on day 4 when MSCs were incubated with
500 MOI Adv-Stat3(-). The amount of virus released
remained steady until day 5 (10
6.1pfu/Ml)(Figure 2B); In
the wild-type group, the concentration in the culture
medium displayed a parallel, but earlier, increase com-
pared to Adv-Stat3(-), and virus was not detected in the
culture medium for the Adv-GFP group. The amount of
intracellular adenovirus in MSCs was also measured. The
amount of virus in Adv-Stat3(-) group greatly increased
from 10
3.0pfu/mL on day 1 to 10
5.8pfu/mL on day 3 and
remained invariable between days 3 and 4, eventually
decreasing to 10
3.7pfu/mL on day 5 (Figure 2C). The
amount in the Adv-wt group exhibited an earlier, but
parallel change as Adv-Stat3(-). The amount of virus in
the Adv-GFP group was unchanged during this period.
In addition, quantitative PCR to detect targeting fiber, a
late structural viral gene whose expression is dependent
on active viral replication, was performed. Adv-Stat3(-)
replicated in MSCs from day 1, and this replication
ended at a low level on day 5 (Figure 2D). In accordance
with the TCID50 experiments, Adv-wt replicated faster
than Adv-Stat3(-), and Adv-GFP did not replicate.
Adv-Stat3(-)-loaded MSCs Selectively Exert an In Vitro
Oncolytic Effect on Breast Cancer and Melanoma Cells
To test the ability of MSCs to deliver CRAd to breast can-
cer and melanoma cells, a co-culture system using trans-
well plates was used. After 72 hours, MSC/Adv-Stat3(-)
induced notable cytopathic effects (CPE) in MDA-MB-231
and MDA-MB-435 cells, but not in HUVEC cells. The
positive CPE in MDA-MB-231 and MDA-MB-435 were
concomitant with viral replication evaluated by in situ
hybridization. However, MSC per se treatment exhibited
no detectable CPE in MDA-MB-231, MDA-MB-435, and
HUVEC cells (Figure 3A). Flow cytometric assays using
t h es a m ec o - c u l t u r es y s t e mc o m p a r e dt h ea p o p t o s i s
caused by MSC, Adv-Stat3(-), and MSC/Adv-Stat3(-)
treatment. After MSC/Adv Stat3(-) treatment, 32.5% ±
4.3% and 35.9% ± 2.3% of MDA-MB-231 and MDA-MB-
435 cells, respectively, were apoptotic (Figure 3B). Adv-
S t a t 3 ( - )a tt h es a m ed o s ec a u s e da p o p t o s i si n2 2 . 2 %±
4.3% and 20.9% ± 4.8% of MDA-MB-231 and MDA-MB-
435 cells, respectively, which is significantly lower than the
Figure 2 Adv-Stat3(-) replicates adequately in MSCs and is eventually released. (A) Cytopathic effects of Adv-GFP, Adv-Stat3(-), and Adv-wt
on MSCs. MSCs were infected with Adv-GFP, Adv-Stat3(-), and Adv-wt at different MOI. The cytotoxic activity was evaluated by crystal violet
staining at each time point. The control without any viral infection is indicated as Ctr. (B) Viral count in the culture medium of MSCs was
expressed as mean ± SD in three independent experiments. MSCs were infected with 500 MOI Adv-GFP, Adv-Stat3(-), and Adv-wt. At each time
point, the culture medium was collected and the viral concentration measured using the TCID50 method. (C) Intracellular viral concentration was
expressed as mean ± SD in three independent experiments. MSCs were infected with 500 MOI Adv-GFP, Adv-Stat3(-), and Adv-wt. At each time
point, the intracellular virus was extracted by three cycles of freezing and thawing and measured using the TCID50 method. (D) DNA replication
of Adv-GFP, Adv-Stat3(-), and Adv-wt in MSCs. MSCs were infected with 500 MOI Adv-GFP, Adv-Stat3(-), and Adv-wt. At each time point, MSCs
were harvested and real-time PCR performed to measure the amount of viral DNA. Results are the means of three independent experiments and
expressed as the ratio with GAPDH. Negative controls omitted templates.
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treatment did not exert an obvious apoptosis effect on
MDA-MB-231 or MDA-MB-435 cells. Significant apopto-
sis was not induced in normal HUVEC cells by any of the
treatments. The co-culture experiments evaluated by flow
cytometry were repeated with different ratios of MSC/
Adv-Stat3(-) in tumor and HUVEC cells. Apoptosis of the
cancer cells significantly increased with an increasing ratio
from 1:100 to 1:1 (P < .05) (Figure 3C); whereas HUVEC
cells continued to have only low levels of apoptosis at any
ratio tested.
Immunoblot analysis of the whole cell lysate from the
lower chambers showed that MSC/Adv-Stat3(-) reduced
the expression of Stat3, p-Stat3, and its downstream tar-
get proteins, including Bcl-xl, c-myc, and Survivin, to a
greater extent than Adv- Stat3(-) in MDA-MB-231 and
MDA-MB-435 cells. However, no obvious change was
found for MSC treatment compared to negative control
(Figure 3D). In HUVEC cells, none of the treatments
produced significant depletion of Stat3 expression
(Additional file 1, Figure S1).
Adv-Stat3(-)-loaded MSCs Preferentially Home to Tumors
in a Time-Dependent Manner
To confirm that Adv-Stat3(-)-loaded MSCs preferentially
engraft in tumors, we examined the homing capability of
Figure 3 MSC/Adv-Stat3(-) selectively exerts in vitro oncolytic effects on breast cancer and melanoma cell lines and suppresses the
Stat3 pathway. (A) Cytopathic effects and virus replication induced by MSC and MSC/Adv-Stat3(-) in MDA-MB-231, MDA-MB-435, and HUVEC
cells. 1 × 10
5 MDA-MB-231, MDA-MB-435, and HUVEC cells were plated in the lower chambers of transwell plates. 1 × 10
4 MSCs pre-infected
with 500 MOI Adv-Stat3(-) for 48 hours or MSCs alone were added in the upper chambers. Phase contrast images of the cells in the lower
chamber were taken after 72 hours and in situ hybridizations targeting viral fiber were performed. Scale bar = 10 μm. Cell nucleuses were
counterstained with DAPI. (B) Apoptosis rates caused by MSC, Adv-Stat3(-), and MSC/Adv-Stat3(-) in MDA-MB-231, MDA-MB-435, and HUVEC cells.
1×1 0
5 MDA-MB-231, MDA-MB-435, and HUVEC cells were plated in the lower chambers of transwell plates. 1 × 10
4 MSCs pre-infected with 500
MOI Adv-Stat3(-) for 48 hours, equivalent Adv-Stat3(-), or MSCs were added in the upper chambers. The cells in the lower chambers were
stained with Annexin-V/PI after 72 hours and analyzed by FACS. (C) Apoptosis in the lower chambers in response to different ratios of MSC/Adv-
Stat3(-). (D) Representative Western blot demonstrating the changes in Stat3, p-Stat3, Bcl-xl, c-myc, and Survivin caused by MSC/Adv-Stat3(-),
Adv-Stat3(-), and MSC. Medium was used as a negative control. *P < .05. Results were expressed as mean ± SD in three independent
experiments.
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establishment of a breast orthotopic xenograft, the mice
were intravenously injected with 1 × 10
6 SPIO-labeled
MSCs. After 24 or 72 hours, the mice were sacrificed and
assessed for the presence of MSCs in various tissues
using Prussian blue staining (Additional file 2, Figure
S2A). MSCs were mainly localized to the tumor periph-
ery at 24 hours. At 72 hours, MSCs were mostly found in
the tumor parenchyma (Additional file 2, Figure S2B).
However, no normal organs (i.e. kidney, muscle, intes-
tines, contralateral normal breast, or heart) showed signs
of MSC engraftment, except for the rare existence in the
lung, liver, and spleen (Additional file 2, Figure S2C).
Cell Tracker Red was introduced to track MSCs in vivo
and ascertain the tumor tropism of Adv-Stat3(-)-loaded
MSCs. One day after in vitro labeling with Cell Tracker
Red, the MSCs were found to display a strong red fluores-
cence (Figure 4A). The labeling efficiencies at different
time points were measured by flow cytometry and there
were over 90% Cell Tracker Red positive MSCs in the first
5 days. After 9 days, we still found high efficiency of more
than 70% (Figure 4B), which supports the sensitivity of in
vivo tracking. Next, we injected 1 × 10
6 Adv-Stat3
(-)-loaded MSCs labeled with Cell Tracker Red into the
tumor-bearing mice. The mice at each time point (n = 3
each; 24, 48, and 72 hours after treatment) were sacrificed
and examined for the presence of MSCs using a fluores-
cence microscope. MSCs were identified by red fluores-
cence, whereas intracellular adenoviruses were examined
using FITC-labeled adenovirus hexon antibody, which
fluoresced green. MSCs carrying Adv-Stat3(-) appeared as
orange in the overlay (Figure 4C). A significant increase in
the number of Adv-Stat3(-)-loaded MSCs occurred with
time (Figure 4D). At 24 hours, we observed considerable
localization of Adv- Stat3(-)-loaded MSCs in the lungs,
liver, and spleen, but it sharp l yd e c r e a s e dt oq u i t eal o w
level by 72 hours. Few Adv-Stat3(-)-loaded MSCs were
detected in other tissues, including the kidneys, muscle,
and intestines, during this period.
Adv-Stat3(-)-loaded MSCs Inhibit Breast Tumor Growth in
Mice
Based on the above results, we hypothesized that the
administration of Adv-Stat3(-)-loaded MSCs allows for
selective delivery of virus to breast tumor in vivo,
improving the therapeutic effect over virus alone. Twenty
days after the establishment of breast orthotopic xeno-
grafts, we intravenously injected 1 × 10
6 Adv-Stat3
(-)-loaded MSCs (n = 5 mice; equivalent Adv-Stat3(-)
and MSCs) at 4-day intervals for 8 doses. Tumor-bearing
mice that received PBS were used as controls (n = 5;
Figure 5A). Compared to the control group, tumor
growth was inhibited by Adv-Stat3(-) but not MSC treat-
ment. At day 52, the mean tumor volume in the Adv-
Stat3(-) group was 248.3 ± 34.2 mm
3,w h i c hw a ss i g n i f i -
cantly smaller than that of the PBS (437.9 ± 36.3 mm
3)
and MSC (485.4 ± 31.6 mm
3)g r o u p s( P < .05). However,
when compared to the MSC/Adv-Stat3(-) group, the
tumor growth in the Adv-Stat3(-) groups tended to be
larger. The mean tumor volume in the Adv-Stat3(-) and
MSC/Adv-Stat3(-) groups at day 52 was 248.3 ± 34.2
mm
3 and 116.5 ± 20.1 mm
3, respectively (P < 0.05; Figure
5B). After measuring the tumor for the last time, the
mice in each group were sacrificed and the tumor masses
separated and analyzed by Western blot and immunohis-
tochemistry. In accordance with the in vitro results,
MSC/Adv-Stat3(-) obviously reduced Stat3, p-Stat3, and
its downstream proteins compared to PBS. Only a slight
reduction in Stat3, p-Stat3, and its downstream proteins
was observed in the Adv-Stat3(-) group. However, we
found no change in the expression of the Stat3 pathway
upon MSC treatment (Figure 5D). Immunohistochemical
analysis revealed notably fewer Ki-67-positive proliferat-
ing cells in MSC/Adv-Stat3(-)-treated mice than mice
treated with Adv-Stat3(-) (P < .05). Also, a significant
reduction in Ki-67-positive cells was observed in Adv-
Stat3(-)-treated mice compared to control mice (P < .05).
However, no significant difference in the number of Ki-
67-positive cells was found between the MSC and control
groups (Figure 5E and 5F). In contrast, a significantly
greater number of CD11b-positive cells which repre-
sented granulocytes and macrophages were found in the
MSC/Adv-Stat3(-) group than the control group.
Although the mice in the Adv-Stat3(-) group had a
higher number of CD11b-positive cells than the control
group, it was not significant (P > .05). Also, no significant
difference was found between the MSC and PBS groups
(P > .05; Figure 5G and 5H).
Adv-Stat3(-)-loaded MSCs Improve the Survival of Breast
Tumor-bearing Mice
Finally, we examined whether Adv-Stat3(-)-loaded MSCs
improve the survival of tumor-bearing mice. Mice were
intravenously treated with PBS (n = 8), MSC (n = 8),
Adv-Stat3(-) (n = 8), or MSC/Adv-Stat3(-) (n = 8) and
followed to determine survival rates. The mice treated
with MSC/Adv-Stat3(-) survived significantly longer than
the other three groups (P < .05; Figure 5C). At the end
point of the follow-up, four mice treated with MSC/Adv-
Stat3(-) were alive, but no mice were alive in the other
three groups. In addition, the mice treated with Adv-
Stat3(-) but not MSC survived longer than PBS-treated
mice (P < .05).
Discussion
The capability of MSCs to incorporate into tumors as a
stromal element allows the stem cell to release anti-
tumor agents from within the tumor [27,30,38]. Recently,
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Page 7 of 12Figure 4 Kinetic distribution of Adv-Stat3(-)-loaded MSCs in a breast orthotopic tumor model.( A )M S C sl a b e l e dw i t h5μMC e l lT r a c k e r
Red. The cells were observed under a fluorescent microscope after 24 hours (upper panel). The corresponding bright field is shown in the lower
panel. Scale bar = 15 μm. (B) Labeling efficiencies of MSCs with Cell Tracker Red at the indicated time points as evaluated by FACS were
expressed as mean ± SD in three independent experiments. (C) Representative images showing the distribution of Adv-Stat3(-)-loaded MSCs in
an orthotopic tumor. 1 × 10
6 Cell Tracker Red labeled MSCs were infected with 500 MOI Ade-Stat3(-). Six hours later, these cells were
intravenously injected into tumor-bearing mice. The mice were sacrificed and frozen sections of tumor prepared and incubated with FITC-
labeled adenovirus hexon antibody after 24 (upper panels), 48 (middle panels), and 72 (lower panels) hours. The sections were counterstained
with DAPI and observed under a fluorescent microscope. Scale bar = 20 μm. (D) Cell number of MSCs in normal tissue from the mice in panel c
at the indicated time points. After incubating frozen sections with FITC-labeled adenovirus hexon antibody, the sections were observed under a
fluorescent microscope. The number of MSCs were counted under ×20 HPF in five random fields and expressed as mean ± SD (n = 3).
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Page 8 of 12MSCs have been reported to deliver CRAd to various
malignant tumors [26,28,32]. However, the kinetic pro-
cess of CRAd-engineered MSC trafficking to tumors and
the release of adenovirus from MSCs is still lacking. To
be delivered by a cellular vehicle, CRAd should be cap-
able to efficiently transduce MSCs. Adam [26] and
Komarova [4] reported that adenoviral vectors bearing 5/
3 or argininine-glycine-aspartic acid (RGD) modifications
on their fiber knobs, instead of wild-type 5 knob, are cap-
able of effectively transducing MSCs. These findings are
consistent with the result that MSCs had scarce expres-
sion of coxsackie and adenovirus receptor (CAR), which
immediately mediates the transduction of wild-type ade-
novirus 5 [39]. However, our findings indicated that ADV
with wild-type 5 knob at MOI of more than 500 MOI can
be highly transduced in MSCs. We speculated that the
contradictive results may be ascribed to the different
virus titers used or other unknown molecules other than
CAR mediating the transduction. In the present study,
w ef o u n dt h a tE 1 A - m u t a n tA d v - S t a t 3 ( - )a t5 0 0M O I
infection exponentially amplified in MSCs up to the
utmost quantity in a sufficient time window, which con-
sequently boosted the tumor apoptosis rate compared to
direct virus treatment. The results can be explained two
ways. First, MSC could function as a manufacturer of
E1A-mutant CRAd, allowing the total amount of virus
required for therapeutic effects to decrease compared to
direct equivalent virus injection. Second, the superior
therapeutic response from treatment with Adv-Stat3
(-)-loaded MSCs could be due to not introducing too
much CRAd initially, which may lead to premature
release of adenovirus before it is delivered to the tumor
site, and avoid too little CRAd, which may restrict the
maximal tumor oncolysis.
Figure 5 MSC/Adv-Stat3(-) inhibits tumor growth and improves survival rates in tumor-bearing mice. (A) Schematic graph showing the
design of the in vivo experiment. (B) Tumor growth in mice treated with MSC, Adv-Stat3(-), or MSC/Adv-Stat3(-). Tumor volume in each group
was expressed as mean ± SD. (n = 5) (C) Survival curves following the administration of MSC, Adv-Stat3(-), or MSC/Adv-Stat3(-). (D)
Representative Western blot analysis of the Stat3 pathway in orthotopic tumors on day 52 after the last measurement of the tumor. (E)
Representative immunohistochemistry images showing Ki67-positive cells (brown) in orthotopic tumors on day 52 after the last measurement of
tumor. (F) Statistical analysis of Ki67-positive cells counted in five random fields from panel E. (G) Representative immunohistochemistry images
showing CD11b-positive cells (brown) in orthotopic tumors on day 52 after the last measurement of tumor. (H) Statistical analysis of CD11b-
positive cells counted in five random fields from panel G. *P < .05, E and G, scale bar = 20 μm.
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Page 9 of 12The tumor migrating tropism of MSCs has been
acknowledged in recent years [26,27,30]. However,
hardly any investigation has been done concerning the
kinetic distribution of the systematic administration of
MSCs in the body, and no consensus exists on how
long before the MSCs are first found in the tumor site.
Mariam [28] detected MSCs in lung metastases 3 days
after intravenous injection, whereas Michael [27]
detected MSCs in lung metastases after 20 days. In our
study, we investigated the homing ability and distribu-
tion pattern of MSCs in a certain course ranging from
24 hours to 72 hours after injection. A considerable
number of Adv-Stat3(-)-loaded MSCs were found in the
lungs, liver, spleen, and tumor periphery at 24 hours.
With time, the number of MSCs in the lungs, liver, and
spleen decreased to an extremely low level by 72 hours,
whereas the number of MSCs in the tumor increased
over this same time period. The localization of MSCs in
the lungs, liver, and spleen was possibly determined to
be a result of either the abundance of blood flow contri-
buting to passive arrest or the phagocytosis of MSC’sb y
macrophages in these organs. After several cycles of
blood circulation, most of the MSCs redistributed to the
tumor parenchyma.
In the in vitro experiment, we found Adv- stat3(-) could
exponentially amplify in MSCs. After 72 hours’ amplifica-
tion, the Adv- stat3(-) began to make a decreased stat3
expression in the MSCs (data not shown) and eventually
released from the carrier at day 4. However, in vivo experi-
ment demonstrated it took no more than 72 hours that
most of Adv-Stat3(-)-loaded MSCs have already arrived at
the tumor sites. It suggests MSCs could carry a sufficient
amount of Adv-Stat3(-) to the tumor sites before they
were lysed by the virus.
The possible direct effects that MSCs may have on the
host should not be neglected. Some studies have presented
intrinsic anti-neoplastic properties in Kaposi’ss a r c o m a
[40] and subcutaneous breast tumors [41]. Various expla-
nations have been proposed for these effects, including
Akt inhibition [40] and the Wnt pathway [41]. Conversely,
Karnoub reported the MSCs promote tumor development
in a subcutaneous breast tumor model [42]. Additionally,
no positive or negative effect of MSCs was revealed by
Sasportas in a glioma model [30]. In our orthotopic breast
tumor model, we did not see any increase or decrease in
tumor growth following direct MSC injection. The dispa-
rate effects of MSCs on tumor growth among these inves-
tigations may be ascribed to the different histological
tumor types and route of MSC administration. Even if
MSCs had a positive effect on tumor progression, the ade-
novirus released from carrier cells can be anticipated to
locally infect and destroy more MSCs, which eliminates
the tumor progression influenced by MSCs. Therefore, the
beneficial outcomes of CRAd-loaded MSCs in tumor
treatment are expected regardless of the positive or nega-
tive effects of MSCs on tumor progression.
In our study, an athymic BALB/c mouse model lacking
T cells, but having normal B cells, macrophages, and NK
cells, was used. In addition to inhibiting tumor growth
through tumor oncolysis and suppressing the Stat3 path-
way, MSC/Adv-Stat3(-) treatment notably increase the
recruitment of CD11b-positive cells in the tumor sites,
which include granulocytes and macrophages. Basing on
the findings reported by Burdelya [43] and Wang [44], we
hypothesize knockdown of stat3 in tumor cells could
cause a rise in multiple inflammatory mediators and make
the tumor cells more immunogenic that result in recruit-
ment of more CD11b-positive cells from peripheral circu-
lation to the tumor site than the control groups. Some
studies have reported infiltrating macrophage could act as
an anticancer role [45,46]. In contrast, there were more
and more cases in which the presence of infiltrating
macrophage was correlated with a poor prognosis [47],
which should not be neglected. The above inconsistency
could be possibly ascribed to the complexity of the tumor/
tumor-associated macrophage (TAM) relationship and the
detailed mechanism needs to be clarified in the further
investigations.
Conclusions
This study presents the kinetic process underlying MSC
trafficking to tumors and the dynamic course of the
amplification and releaseo fE 1 A - m u t a n tC R A df r o m
MSCs. MSCs not only act as a cell carrier, but also
allow the replication of CRAd, significantly enhancing
the oncolytic effect and resulting in an augmented
tumor inhibition efficiency.
Additional material
Additional file 1: Figure 1. Representative Western blot demonstrating
the changes in Stat3 caused by MSC/Adv-Stat3(-), Adv-Stat3(-), and MSC
in HUVEC cells. Medium was used as a negative control.
Additional file 2: Figure 2. MSC preferentially homes to pre-established
breast orthotopic tumors. (A) Schematic graph showing the design of the
experiment. (B) Representative images showing the distribution of MSCs in
the tumor. 1 × 10
6 SPIO-labeled MSCs were intravenously injected into
tumor-bearing mice. The mice were sacrificed and frozen sections
prepared at 24 hours (upper panels) and 72 hours (lower panels). Prussian
blue staining was performed to detect the presence of MSCs in the tumor
(left columns, black arrows), and the sections were counterstained with
nuclear fast red. Sequential sections stained with H&E are shown in the
right columns. (C) Representative images showing the distribution of
MSCs in normal tissues. 72 hours after intravenous injection of 1 × 10
6
SPIO-labeled MSCs, the mice in panel b were sacrificed and their organs
prepared for frozen sections followed by Prussian blue and nuclear fast
red staining. B, scale bar = 10 μm; C, scale bar = 20 μm.
List of abbreviations
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adenovirus receptor; MOI: multiplicity of infection; PBS: phosphate-buffered
saline.
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